



PCT/GB 2004 / 0 0 1 2 6 4



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport

South Wales  
NP10 8QQ

REC'D 04 MAY 2004

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 20 April 2004

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

THE PATENT OFFICE  
B

27 MAR 2003

NEWPORT



28MAR03 E795766-1 D10100  
P01/7700 0.00-0307089.3

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

## Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

CPG/P/222/GBA

2. Patent application number

(The Patent Office will fill in this part)

0307089.3

27 MAR 2003

3. Full name, address and postcode of the or of each applicant (underline all surnames)

699 767 0005

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

The Secretary of State for Defence  
DSTL  
Porton Down  
Salisbury  
Wiltshire  
SP4 0JQ  
GB

4. Title of the invention

Live Vaccine Strain

5. Name of your agent (if you have one)

Carol P. Greaves et al.

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Greaves Brewster  
Indigo House  
Cheddar Business Park  
Wedmore Road  
Cheddar, Somerset  
BS27 3EB  
GB

Patents ADP number (if you know it)

78859 08002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

Yes

**Patents Form 1/77**

9. Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

001010 1-8212773 2094-25

Continuation sheets of this form

Description

25

Claim(s)


3

Abstract

1

Drawing(s)

7

+7 

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

One

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature



Date

27/3/03

12. Name and daytime telephone number of person to contact in the United Kingdom

Carol Greaves 01934 745880

**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

**Notes**

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Live vaccine strain

The present invention relates to the live strains of *Francisella* species for use as prophylactic or therapeutic vaccines, to compositions containing these strains, and their use in preventing or treating disease.

*Francisella tularensis* is the causative agent of tularemia and is a member of the family *Francisellaceae*. There are three species within the genus *Francisella*: *F. tularensis*, *Francisella novicida* and *Francisella philomiragia*. 16S ribosomal DNA sequence analysis has placed the genus *Francisella* as a member of the  $\gamma$  subclass of the proteobacteria. The *F. tularensis* species was originally divided into two biotypes, A and B, but recently four recognisable biotypes have been proposed. *F. tularensis* subspecies *tularensis*, previously known as Type A or subspecies *nearctica*, is recognised as the most virulent. It is responsible for human cases in North America and Europe and causes severe disease in mammals, especially rabbits. *F. tularensis* subspecies *palaeartica*, also known as *holartica* or Type B, is found in Europe, Asia and North America and is less virulent in humans than *F. tularensis* subspecies *tularensis*. *F. tularensis* subspecies *mediaasiatica* has been isolated from central Asia and subspecies *palaeartica japonica* is found only in Japan.

*F. tularensis* subspecies *philomiragia* was originally known as the "Philomiragia" bacterium before being renamed *Yersinia philomiragia*. It was finally placed in the *Francisella* genus on the basis of biochemical tests and cellular fatty acid analysis. Although *F. tularensis* subspecies *novicida* and *F. tularensis* subspecies *philomiragia* are considered pathogenic to humans they pose only a small risk.

*F. novicida* was classified into the genus *Pasteurella* in 1955, but then reclassified in 1959 into the genus *Francisella*. It

was initially considered a separate species to *F. tularensis*, however recently it has been proposed that it should be designated *F. tularensis subspecies novicida* because of the similarities between the two species. Both of these designations are utilised herein.

At the genetic level this similarity to *F. tularensis* is greater than 99% and the two species are chemically and antigenically very similar, demonstrating strong serological cross-reactivity. However the applicants have found that *F. novicida* can be differentiated from *F. tularensis* on the basis of less fastidious growth requirements and the ability to produce acid from sucrose. *F. novicida* is fully virulent in the mouse model with a LD50 of 1.76cfu, but has reduced virulence in humans compared to *F. tularensis*.

Human cases of tularemia usually result from a bite from a vector such as biting flies, ticks and mosquitoes that have recently fed on an infected animal. However, there have been reported cases of infections caused by contact with dead animals, infectious aerosols, and ingestion of contaminated food and water. Hunters, veterinarians, walkers and farmers are at the greatest risk of contracting tularemia because they are likely to come into contact with infected animals. The incidence of tularemia in humans is usually low, but an increase in the number of cases is observed when there is an epidemic in the local animal reservoir.

In the 1940s there were attempts to make killed vaccines against tularemia consisting of whole killed cells or cell extracts, however these failed to give protection against challenge with fully virulent strains. Therefore efforts were concentrated on the production of a live vaccine. Live attenuated strains were developed in the former Soviet Union by repeatedly passaging the bacterium on media containing antiserum. Several strains were



suitably attenuated for use as a vaccine and were used as such, either alone or in a mixed culture vaccine.

5 In 1956 a mixture of strains of *Francisella tularensis* were transferred from the former Soviet Union to the United States. From these a suitably attenuated strain was isolated and tested for safety and efficacy and was designated *F. tularensis* live vaccine strain (LVS). The vaccine is delivered via the scarification route using a dose of 0.06 ml and is followed by  
10 yearly boosters. Retrospective studies on the efficacy of the LVS vaccine based on laboratory acquired infections have shown that it affords good but not complete protection against typhoidal tularemia leading to a dramatic decrease in cases. However, the incidence of the ulceroglandular form as not  
15 decreased but there appears to be a reduction in the severity of the clinical symptoms. Studies using *F. tularensis* LVS have shown that it is cell-mediated immunity that correlates with protection. Protein antigens on the surface of the bacterium induce the cell-mediated response however a large number of  
20 antigens appear to be important because there is no bias in the response towards one particular antigen. It has been found that the cytokines interleukin-1 and interferon- $\gamma$  are important in providing resistance to infection. The humoral response induced by carbohydrate antigens on the bacterium also have a role in  
25 protection but can only protect against challenge by strains with reduced virulence.

The LVS vaccine is not registered and was only used to vaccinate at-risk personnel under special license, however these licenses  
30 have now been withdrawn. The main reason for this is that the genetic changes responsible for the attenuating phenotype are not understood at the molecular level. Therefore there is the possibility that the vaccine strain could revert back to the fully virulent form. A new live attenuated vaccine is therefore  
35 required.

The applicants have found that by modifying strains of *Francisella* in a particular way, useful vaccine strains can be produced.

---

5 The present invention therefore provides a strain of *Francisella*  
species wherein a gene which encodes an enzyme in the purine  
pathway has been inactivated, and which is able to produce a  
protective immune response in an animal, for use as a live  
prophylactic or therapeutic vaccine against infection by said  
10 *Francisella* species.

The purine pathway and enzymes that are active in it are listed  
in Figure 1 hereinafter. Determination of those of the genes  
which, if inactivated, still produce a protective immune  
15 response but do not result in a full-blown infection with virus  
can be determined by transforming cells using recombinant DNA  
technology, and testing the resultant transformants in animals.

The applicants have found that in order to obtain strains which  
20 are attenuated and so do not cause disease, but also are  
protective, it is preferable to inactivate genes which encode  
enzymes which are active early in the pathway. By "early", is  
meant enzymes which are active before the pathway branches, and  
in particular, the first six enzymes in the pathway.

25 In particular, the applicants have found that inactivation of  
the *purF* gene produces a live vaccine strain. As illustrated  
hereinafter, a strain of *F. novicida* with an inactivated *purF*  
gene is attenuated in vivo when compared to a wild-type strain.

30 It has been found to be able to survive and replicate in  
macrophages and it is suggested that the levels at which this  
occurs are sufficient to stimulate a immune response before it  
is cleared by the immune system. This strain has found to be  
protective in mice and so may give rise to a live vaccine.

35

Suitably the gene is other than *purA*. This gene converts inosine monophosphate to adenosine monophosphate (AMP) and its inactivation produces a requirement for adenine. A *purA* mutant has been produced in other pathogens, in particular *Salmonella enterica* serovar *typhimurium* and *Edwardsiella ictaluri* and these have proven to be attenuated, and in some cases also protective. As illustrated hereinafter however, the applicants have found that although inactivation of this gene in *F. novicida* severely affects its growth in vitro and causes a high degree of attenuation in vivo, it was not adequately protective of mice against subsequent challenge with *F. novicida*. It is possible that the inability of the *purA* mutant to survive in macrophages means that it is unable to colonise the mouse cells for a sufficient period of time to stimulate a protective immune response.

However, the gene may comprise *guaA*. The *guaA* gene encodes the enzyme that converts inosine monophosphate (IMP) to guanosine triphosphate (GTP) (Figure 1). A *guaA* mutant has been produced in *Salmonella enterica* serovar *typhimurium* and has been shown to be attenuated. Regions of the *guaA* gene from *F. novicida* have been amplified using PCR and sequenced. The data was compared to the emerging genome sequence data for *F. tularensis* strain SCHU4, and a 96-97% identity between the two biovars was observed for the regions sequenced. Therefore, *F. novicida* would be a good model for *F. tularensis* in this respect.

The strain of the invention suitably has a further defined mutation so as to reduce the risk of the bacterium reverting to a virulent form. In this case, the mutation is in a gene which is selected so that the strain is suitably attenuated, but can still retain the ability to stimulate a sufficient immune response to provide long term protection. Suitable additional mutations can be identified using conventional methods, and examination and analysis of the current live vaccine strain (LVS) may assist in the identification, since this strain has



demonstrated that protection can be achieved using an attenuated strain.

---

Gene inactivation can be carried out using any of the  
5 conventional methods. Typically, the strain is transformed with  
a vector which has the effect of downregulating or otherwise  
inactivating the gene. This can be done by mutating control  
elements such as promoters and the like which control gene  
expression, by mutating the coding region of gene so that any  
10 product expressed is inactive, or by deleting the gene entirely.  
Alternatively, the gene can be inactivated at the RNA or protein  
level, by transforming the cell so that it expresses a sense or  
anti-sense construct which binds to DNA or RNA encoding the gene  
to prevent transcription thereof.

15 It may also be possible to inactivate the product at the protein  
level, by causing the cell to express a protein which binds to  
and inactivates the enzyme.

20 Preferably however, the gene is inactivated by complete or  
partial deletion mutation or by insertional mutation.

Transformation can be carried out in a variety of ways. It has  
been reported in the literature that *F. novicida* U112 can be  
25 transformed by electroporation and chemically. The applicants  
have found however that transformation is suitably carried out  
using cryotransformation, as illustrated hereinafter.  
Cryotransformation has been used to produce an isogenic defined  
*purA* mutant in *F. novicida*, showing not only that the particular  
30 construct can undergo homologous recombination in a *Francisella*  
host, but also that *F. novicida* is amenable to  
cryotransformation. In this method, cells are mixed with  
transformation buffer and plasmid DNA, and then frozen for a  
period, for example in liquid nitrogen. Recovered cells are  
35 incubated and then cultured and selected using conventional  
methods.

In particular, the strain used is a *Francisella tularensis*, such as *F. tularensis* subspecies *novicida* or *F. tularensis* subspecies *tularensis*. Preferably the strain is a strain of *Francisella tularensis* subspecies *tularensis*.

5

These strains provide useful vaccines. They are therefore preferably formulated into pharmaceutical compositions, in which they are combined with a pharmaceutically acceptable carrier. These form a further aspect of the invention.

10

Suitable carriers may be solid or liquid carriers as is understood in the art. They may suitably be formulated for administration to mucosal surfaces (for example for oral use, of for administration by inhalation or insufflation) or for  
15 parenteral administration.

In particular they are formulated as sterile aqueous or oily solutions for intravenous, subcutaneous, intramuscular or intramuscular dosing.

20

Alternatively they are formulated for administration to mucosal surfaces and in particular for intranasal application.

Compositions are suitably prepared in unit dosage forms, as  
25 conventional in the art. They are administered at dosages which are determined using clinical practice, and depend upon factors such as the nature of the patient, the severity of the condition, and the precise vaccine strain being employed. Typically dosage units will comprise  $10^5$  -  $10^8$  cfu. Dosages may  
30 be boosted as appropriate or necessary.

Compositions may also contain further immunogenic reagents which are effective against *F. tularensis* or other diseases. They may further contain other agents such as adjuvants and the like,  
35 which enhance the hosts immune response to the vaccine.

In a further aspect, the invention provides the use of a strain of *Francisella* species wherein a gene which encodes an enzyme in the purine pathway, such as the *purF* gene, has been inactivated, and which is able to produce a protective immune response in an animal, in the preparation of a live prophylactic or therapeutic vaccine against infection by said *Francisella* species.

In yet a further aspect, the invention provides a method of preventing or treating infection by a *Francisella* species, which method comprises administering to an animal an effective amount of a live strain as described above, or a composition as described above.

In particular, the method is used to protect or treat infection by *Francisella tularensis* subspecies *tularensis*.

Novel strains which are suitable for vaccine use form a further aspect of the invention. In particular, the invention provides a strain of *Francisella tularensis* subspecies *tularensis* wherein a gene that encodes a *purA* gene has been inactivated.

The invention will now be particularly described by way of Example with reference to the accompanying diagrammatic drawings in which:

Figure 1 shows the de novo purine pathway;

Figure 2 illustrates a construct used in the examples, the pUC18 *guaA'* construct;

Figure 3.1 shows the results of a PCR to amplify the *purA* gene, using the screen F and screen R primers, wherein lane 1: shows molecular weight markers (DRigest III) Roche, size shown in base pairs), lane 2:*F. novicida* *purA* 1, lane 3:*F. novicida* *purA* 2, lane 4:*F. novicida* *purA* 3, lane 5:*F. novicida* *purA* 6, lane 6:*F. novicida* *purA* 7, lane 7:*F. novicida* *purA* 25, lane 8:*F. novicida*

U112, lane 9: *F. tularensis* HN63 purA integrant 15, lane 10: control- dH<sub>2</sub>O.

Figure 3.2 shows the results of a PCR to amplify the chloramphenicol cassette, using the CAM BamF and CAM BamR primers, wherein lane 1: shows molecular weight markers (DRigest III) Roche, size shown in base pairs), lane 2: *F. novicida* purA 1, lane 3: *F. novicida* purA 2, lane 4: *F. novicida* purA 3, lane 5: *F. novicida* purA 6, lane 6: *F. novicida* purA 7, lane 7: *F. novicida* purA 25, lane 8: *F. novicida* U112, lane 9: *F. tularensis* HN63 purA integrant 15, lane 10: pGEM CAM, lane 11: control- dH<sub>2</sub>O.

Figure 3.3 shows the results of a PCR to amplify the *sacB* gene, using the SacBFor and sacBRev primers, wherein lane 1: shows molecular weight markers (DRigest III) Roche, size shown in base pairs), lane 2: *F. novicida* purA 1, lane 3: *F. novicida* purA 2, lane 4: *F. novicida* purA 3, lane 5: *F. novicida* purA 6, lane 6: *F. novicida* purA 7, lane 7: *F. novicida* purA 25, lane 8: *F. novicida* U112, lane 9: *F. tularensis* HN63 purA integrant 15, lane 10: pGEM *sacB*, lane 11: control- dH<sub>2</sub>O.

Figure 4.1 shows a Southern blot of *F. novicida* and *F. tularensis* DNA probed for the *purA* gene after digestion with MluI, wherein lane 1: shows the results for *F. novicida* purA 1, lane 2: *F. novicida* purA 2, lane 3: *F. novicida* purA 3, lane 4: *F. novicida* purA 6, lane 5: *F. novicida* purA 7, lane 6: *F. novicida* purA 25, lane 7: *F. tularensis* HN63 purA integrant 15, lane 8: *F. tularensis* Schu4, lane 9: *F. novicida* U112, lane 10: Molecular size marker, sizes indicated in kilobase pairs.

Figure 4.2 shows a Southern blot of *F. novicida* and *F. tularensis* DNA probed for the *purA* gene after digestion with MluI, wherein lane 1: shows the results for Molecular size marker, sizes indicated in kilobase pairs, lane 2: *F. novicida* purA 2.1, lane 3: *F. novicida* purA 2.2, lane 4: *F. novicida* purA 2.3, lane 5: *F.*

novicida purA 2.4, lane 6: *F. novicida* purA 2.5, lane 7: *F. novicida* purA 3.1, lane 8: *F. novicida* purA 3.2, lane 9: *F. novicida* purA 3.3, lane 10: *F. novicida* purA 3.4, lane 11: *F. novicida* purA 3.5, lane 12: *F. novicida* purA 3.6, lane 13: *F. novicida* purA 3.7, lane 14: *F. novicida* purA 3.8, lane 15: *F. tularensis* HN63 purA integrant 15, lane 16 *F. tularensis* Schu4, lane 17: *F. novicida* U112, lane 18: Molecular size marker, sizes indicated in kilobase pairs.

10 Figure 5 shows the growth after 48 hours of *F. novicida*, *F. novicida* CG57 and *F. novicida* purA 1 in various supplemented media.

15 Figure 6 is a graph showing *F. novicida* U112 and *F. novicida* GC57 growth over 24 hours in CDM.

Figure 7 illustrates the growth of *F. novicida*, *F. novicida* CG57 and *F. novicida* purA 1 in J774 mouse macrophages with 95% confidence intervals.

20

### Example 1

#### Preparation of transformed strains

#### Materials and Methods

#### Bacterial Strains

25 Table 1

Strain	Details	Source/Supplier
<i>E. coli</i> DH5 $\alpha$	F'/endA1 hsdR17 ( $r_k^-$ $m_k^+$ ) Sup E44 thi-1 recA1 gyrA (nalR) $\Delta$ (thyA) 57 hsdS3 ( $r_k^-$ $m_k^+$ )	Life Technologies
<i>F. novicida</i> U112	Wildtype	ATCC
<i>F. novicida</i> CG57	TnMax2. Em <sup>R</sup>	Dr F Nano
<i>F. novicida</i> CG57::GFP	TnMax2. Em <sup>R</sup>	see hereinafter



Strain	Details	Source/Supplier
<i>F. novicida</i> purA	$\Delta$ purA. Cm <sup>R</sup>	see hereinafter

### Plasmids

Table 2

Plasmid	Details	Source
pKK202	Tc <sup>R</sup> Cm <sup>R</sup>	F.O.I. Sweden {Norqvist, 1996 #1}
pUC18	Amp <sup>R</sup>	New England Biolabs
pUC18 purA'	$\Delta$ purA. Cm <sup>R</sup>	
pUC18 guaA'	$\Delta$ guaA. Cm <sup>R</sup>	see hereinafter

5 The pUC18 guaA' plasmid was constructed by amplifying two sections of the *gua* gene plus flanking regions by PCR. The primer pairs GUA2For/GuaABg1R and GuaA3Rev/RevABg1F were used in the amplification. The two fragments were then cloned into pUC18 on the XbaI and SacI sites. A chloramphenicol cassette, amplified by PCR using the primers CAM Bg1F and CAM Bg1II, was  
10 inserted between the two sections of the gene on an engineered Bg1II site (Table 3). The *sacB* gene from the plasmid CVD422 was cloned into the pUC18 backbone on the SacI restriction site (Figure 2).

15 Regions of the *purA* gene were amplified from *F. novicida* U112 template DNA and sequenced. The sequenced regions showed a 91-98% identity to the *F. tularensis* strain SCHU4 genome sequence. A *purA* construct was made using the same strategy as described above for the *guaA* construct.

20

### Growth conditions

*E. coli* strains were grown in Luria-Bertani (LB) media at 37°C. *F. novicida* was grown on supplemented blood cysteine glucose agar, in Chamberlains defined media, Tryptone soya broth  
25 containing 0.1% cysteine or in MCPH broth containing 2% glucose. Selective media was supplemented with antibiotics to the following concentrations: ampicillin at 55µg/ml, chloramphenicol at 30µg/ml, tetracycline 13.5µg/ml.

### Freezer stocks

For *E. coli* strains, 100% glycerol was added to overnight cultures to give a final concentration of 30% before storage at -70°C.

- 5 *F. novicida* cells were harvested from two spread plates and resuspended in a 1ml volume of 30% glycerol in phosphate buffered saline.

### Restriction digests

- 10 Plasmid digests were set up containing 2µl of plasmid DNA, 1µl of each enzyme required, 1µl of a compatible buffer and the volume made up to 10µl with dH<sub>2</sub>O. Digests were incubated at 37°C overnight.

### 15 Agarose gel electrophoresis

PCR products and digests were separated on a 0.7% (wt/vol) agarose-TAE (Tris-acetate EDTA) gel containing 0.5µg/ml ethidium bromide per ml and run against DRigest III markers (Amersham Pharmacia Biotech).

20

### Primers and Polymerase chain reaction

The gene fragments were amplified from *F. novicida* DNA using the polymerase chain reaction (PCR) using 30 cycles at 94°C (30 s), 55°C (30 s), 72°C (60 s) followed by 72°C (10 min) and 4°C. The

- 25 Perkin Elmer 9600 GeneAmp PCR system was used. Primers used are shown in Table 3.

**Table 3**

Primer	Sequence 5' to 3'	No*
CAM BamF	CGC GGA TCC GTA AGA GGT TCC AAC TTT CAC	1
CAM BamR	CGC GGA TCC TTA CGC CCC GCC CTG CCA CTC ATC	2
sacBFor	CGA TCT CAA GAA GCA GAC CGC TAA CAC A	3
sacBRev	CGA GCT CAT AGT TCA TAT GGG ATT CAC C	4
screen F	GTA GAA TTC GTA GGT GTG GTT GGT TAG	5
screen R	GTA ACT TGC TGT CCT GAA TAG TCT TGA	6
GuaA2For	TGC TCT AGA TAT AGC TAT TGC CGT AGG AAT	7
GuaABglR	CGT GCA AGA TCT GCC ATT TAG CAT TCT CTA	8

Primer	Sequence 5' to 3'	No*
GuaA3Rev	CGA GCT CCA GCG CCA ATA CCA GCA CCA	9
GuaABglF	GCA CGT AGA TCT AGC GTA GAT ATG AGT ATG	10

\*SEQ ID NO

#### Isolation of plasmid DNA

Plasmid DNA was isolated using the Qiagen mini and maxi plasmid isolation kits (Basingstoke, UK) as detailed in the  
5 manufacturer's instructions.

#### Genomic DNA extractions

*F. novicida* U112 and *F. novicida* purA mutant DNA was isolated using the Puregene DNA Isolation kit (Gentra systems) according  
10 to the manufacturer's instructions. The DNA was resuspended in 50µl of DNA hydration solution and incubated overnight at room temperature. The DNA was stored at -20°C.

#### Transformation methods

15 To establish an optimal transformation method, the efficiency of transforming *F. novicida* U112 using a range of methods was investigated using the stably replicating shuttle plasmid pKK202. Cryotransformation was found to be the most effective  
20 technique.

#### Cryotransformation

The cells from two *F. novicida* U112 spread plates were harvested and resuspended in 400µl 0.2M KCL of pipetting. A 25µl vlume of bacterial suspension were mixed with 25µl of transformation  
25 buffer. For each positive sample 5µl of plasmid DNA were added and for the negative control 5µl of dH<sub>2</sub>O. The samples were incubated at room temperature for 10 min before being frozen for 5 min by immersion in liquid nitrogen. The samples were removed from the liquid nitrogen and incubated at 37°C for 5 min.  
30 The cells were spotted onto a supplemented BCGA plate and incubated at 37°C for 4 hr. The cells were harvested from the plate and resuspended by pipetting in 400µl of 0.2M KCl. Aliquots of 100µl were plated onto supplemented BCGA

chloramphenicol plates. For pKK202, 100µl aliquots were also plated onto supplemented BCGA tetracycline plates. The plates were incubated at 37°C.

---

- 5 This cryotransformation of *F. novicida* with the plasmid pKK202 yielded transformants at a frequency of  $5.8 \times 10^{-1}$  per ng DNA. The method was also effective for the transformation of pKK202 into *F. tularensis* HN63.

10 **Competent *F. novicida* cells for electroporation**

- F. novicida* was grown in TSB-C with shaking at 37°C to an early to mid-exponential growth phase ( $OD_{600nm}$  0.6), 40ml volumes of culture were spun at 12000g for 10 min and then the pellet resuspended in 40ml 500mM sucrose. This washing step was repeated and then the pellet was resuspended in 10ml 500mM sucrose. After a 4 min centrifugation step at 12000g the pellet was resuspended in 160µl of 500mM sucrose. Glycerol competent cells were made by washing the cells in 10% glycerol using the method described above.

20

**Electroporation**

- For each electroporation 40µl aliquots of cell suspension were added to a 0.2cm gap electroporation cuvette. A total of 200ng of plasmid DNA in a 3µl volume of dH<sub>2</sub>O was added prior to electroporation. Electroporation was conducted using a Gene Pulser (Bio-Rad) at a voltage of 1.5kV, a capacitance of 25µF and a resistance setting of 200Ω.

**Southern blotting**

- 30 For each digest 2-3µg of DNA, 15 U of restriction enzyme (NsiI or MluI (Roche)) and 1.5µl of a compatible buffer were used in a final volume of 15µl. The digests were incubated at 37°C overnight. The digested DNA was separated on a 0.7% agarose gel, dig labelled markers were included on the gel as standards (DNA molecular weight marker II DIG-labelled, Roche).

After the gel had run it was washed in denaturing solution for 45 min. It was then transferred into neutralising buffer for 30 min followed by a second wash for 15 min in fresh buffer. Capillary action using 10X SSC was used to transfer the DNA from the gel to a positively charged nylon membrane overnight. The membrane was air dried for 30 min and then baked at 120°C for 30 min.

The membrane was prehybridised by incubating the membrane at 37°C for 1 hr in DIG-Easy Hyb solution (Sigma).

The purA probe was synthesised by PCR with the primers purABamF and purARev (Table 3) using DIG labelled dNTPs. For hybridisation, 2500 µg of probe was boiled for 8 min and placed on ice, this was added to 100 ml DIG Easy Hyb solution (Sigma) and the membrane was incubated in this overnight at 37°C.

The membrane was washed twice with 2XSSC+0.1% SDS for 5 min at room temperature and twice with 0.1XSSC+0.1% SDS at 68°C for 15 min.

The membrane was then rinsed for 3 min in 1x wash buffer (Malic acid buffer + 3% Tween 20) and then incubated in 1.5x blocking solution for 45 min at room temperature. (Blocking solution - DIG block + 1X malic acid buffer.)

The block was removed and replaced with fresh 1.5x blocking solution containing antidigoxigenin-AP Fab fragment antibody at a dilution of 1:10,000. This was incubated for 30 min at room temperature. The membrane was washed twice for 15 min in 1x wash buffer at room temperature then allowed to equilibrate in detection buffer.

Approximately 20 drops of the substrate disodium 3-(4-methoxyspiro {1,2-dioxentane-3,2'-(5'chloro)tricyclo[3.3.1.1<sup>3,7</sup>]decan}-4-yl) phenyl phosphate



(cspd) was applied to a transparent polyethylene folder. The membrane was placed on the plastic and a further 20 drops of cspd substrate applied to the membrane. The remaining plastic was folded over and the membrane and was incubate for 15 min at room temperature and then for a further 15 min at 37°C. The membrane was exposed to Lumi-film chemiluminescent detection film. The film was then developed in developing solution (Kodac) and then fixed in fixing solution (Kodac). It was then washed in water and allowed to dry.

#### Macrophage assay

Bacterial cells from half a spread plate were resuspended in 3ml L-15 containing Glutamax and 10% final conc. foetal calf serum (Life Technologies). The spectrophotometer reading of this suspension was taken at an optical density of 600nm. This suspension was suitably diluted to give an approximate concentration of  $1 \times 10^9$  cfu/ml. An aliquot of this suspension was serially diluted and plated onto BCGA + supps plated, which were incubated at 37°C to determine the viable count.

The L-15 was aspirated from each well and 100µl of suspension overlaid onto the macrophages. This was repeated for 6 plates (each with 2 wells), plus a control well. Each well contained  $1 \times 10^8$  macrophages and therefore each monolayer was infected with a multiplicity of infection of 10. The cells were incubated for 55 min at 37°C. The media was aspirated and each well was overlaid with L-15 containing 10µg/ml gentamycin. The cells were incubated at 37°C for 1 hr. The media was then removed and replaced with L-15 containing 2µg/ml gentamycin. This was T0.

At this timepoint two wells for each bacterial strain were aspirated and the macrophages washed twice with PBS, 1ml of dH<sub>2</sub>O then added to each well. The macrophages were then incubated at room temperature for 5 min before they were disrupted by pipetting thirty times. The cell lysate was then serially diluted in PBS and suitable dilutions were plated onto BCGA +

supp plates, which were incubated at 37°C for two days. Further time points were taken at 4, 21, 29, 48 and 72 hours.

### Results

#### 5 Recovery of *F. novicida* pUC18 *purA* transformants

*F. novicida* *purA* transformants were recovered on selective media after three separate cryotransformations. Using the PCR primer pair screenF and screenR two of the transformants were identified as integrants whereas the other thirty six clones  
10 appeared to be defined mutants (Figure 3.1). A PCR, using the primers sacBFor and sacBRev which amplify the *sacB* gene, confirmed the presence of the gene from integrant DNA but its absence from mutant DNA (Figure 3.2). For all the clones that were screened the chloramphenicol gene was successfully amplified  
15 using the PCR primers CAMBamF and CAMBamR (Figure 3.3).

#### Southern blotting

Genomic DNA from *F. novicida* *purA* mutants 1, 2, 3, 6, 7, 25, 2.1-2.5, 3.1-3.8, *F. tularensis* integrant 15, *F. tularensis*  
20 SCHU4 and *F. novicida* was digested with the restriction endonuclease *MluI*. The digest was analysed by Southern blotting and probed for the *purA* gene. The probed fragment was the same size for all the mutants and showed the size increase in comparison to *F. novicida* corresponding to the chloramphenicol  
25 cassette (Figures 4.1, 4.2). The southern blot was repeated using the restriction enzyme *NsiI* (Data not shown). These results also confirmed the presence of the chloramphenicol cassette.

30 It was therefore established that integrants and mutants could be differentiated on the basis of PCR and southern blotting results.

#### Selection on sucrose

35 The *sacB* gene had been incorporated into the construct as a counterselectable marker so that once integration of the plasmid

had occurred double crossover mutants could be selected for on sucrose. However the majority of the transformants obtained has ~~lost the *sacB* gene without the need for selection.~~ In the case of the two integrants these strains were grown in the presence of 5% sucrose in CDM and on BCGA-suppl+10% sucrose to select for the double crossover events. Colonies that grew in the presence of sucrose were screened by PCR using the screenF and screenR primers. All the clones tested proved to be integrants and appeared to be insensitive to the sucrose. Therefore, in this case, sucrose selection was not effective. This may be due to the *sacB* gene not being expressed properly.

The *F. novicida* *purA* mutants were isolated without any sucrose selection, which implies that after integration of the plasmid the double crossover event spontaneously occurred. This is not unlikely because the large homologous DNA flanking regions would make plasmid in the integrated state unstable, this event has also been recorded in other species such as *M. tuberculosis*. However, this hypothesis contradicts the observations that the two integrants obtained appear to be stable and have not subsequently undergone the second crossover event. It is possible that in these clones the plasmid has integrated in a way that prevents the second crossover event occurring.

## 25 *F. novicida* CG57

For comparison with *F. novicida purA*, *F. novicida* CG57 was provided by Dr. F. Nano. This strain was identified during a screen of *F. novicida* mutants generated using the transposon TnMax2 as being comprised in its ability to grow in mouse macrophages. The interrupted gene was identified as *purF*, which encodes the enzyme amidophosphoribosyltransferase {Gray, 2002 FEMS Microbiology Lett 2002 Sept 24; 215(1): 53-6}. It may also be prepared using a strategy similar to that described above in reflection to the *purA* mutant. This catalyses the first step in the *de novo* synthesis of purines converting

phosphoribosylpyrophosphate (PRPP) to 5-phosphoribosylamine (PRA) (Figure 1).

#### **Growth of *F. novicida purA* in vitro**

- 5 Inactivation of the *purA* gene produces a requirement for adenine, in Chamberlains defined media (CDM) the only source of adenine was thought to be spermine. Therefore to investigate the adenine auxotrophic phenotype of *F. novicida purA*, clone 1 was grown in complete CDM and in spermine deficient CDM. It was  
10 also grown in spermine deficient CDM supplemented with varying concentrations of adenine (Figure 5). An adenine concentration of 25µg/ml was sufficient to enable *F. novicida purA 1* to grow to a level comparable with *F. novicida* U112. It was also confirmed that the other *purA* mutants required the provision of  
15 adenine to grow in spermine deficient CDM (Data not shown). The inclusion of *F. novicida* CG57 demonstrated that the provision of adenine only affected the growth of the *purA* mutant.

#### **Growth of *F. novicida* CG57 in vitro**

- 20 Disruption of the *purF* gene leads to an auxotrophic requirement for purines therefore to characterise the phenotype of *F. novicida* CG57 it was repeated sub-cultured in CDM with and without spermine. Sub-culture inhibited the growth of the bacterium in both CDM and CDM spermine (Figure 6).

25

#### **Phenotype of *F. novicida purA 1* and *F. novicida* CG57 in vitro**

- Failure of the *F. novicida purA 1* to grow in CDM with and without spermine suggested that the strain was either unable to utilise spermine as a source of purines or that the supply of  
30 purines in CDM was insufficient to compensate for the inactivation of the *purA* gene. Provision of a source of adenine allowed the *purA* mutant to grow which confirmed the phenotype characteristic of the mutation.

- 35 *F. novicida* CG57 was initially able to grow in CDM without spermine however the rate of growth decreased after repeat

passaging in spermine deficient CDM. This suggested that there are intracellular stores of intermediates and/or substrates that for a limited period can be utilised by the bacterium to compensate for the inactivated gene.

5

#### Mouse macrophage assay

The growth of *F. novicida* U112, *F. novicida* CG57 and *F. novicida* purA clone 1 was studied in J774 mouse macrophages (Figure 7). The number of bacteria used to infect each well was determined (Table 4).

10

Table 4

Strain	Number of bacteria per well
<i>F. novicida</i> U112	$6.65 \times 10^8$ cfu
<i>F. novicida</i> purA 1	$1.61 \times 10^8$ cfu
<i>F. novicida</i> CG57	$1.17 \times 10^9$ cfu

It was observed that the *F. novicida* purA clone 1 entered the macrophages at a 1000 fold higher rate than the wildtype but over the first 21hrs number of bacteria recovered only increased slightly. From 21 to 72 hrs the number of bacteria recovered gradually dropped and microscopic examination of the macrophages showed that the monolayer remained intact throughout the assay.

20

The number of bacteria recovered over the first 21 hrs for *F. novicida* U112 and *F. novicida* CG57 increased by four orders of magnitude. At subsequent time points the number of bacteria enumerated fell, however microscopy examination of the macrophages revealed that the monolayer was breaking up. These results show no difference in the rate of growth between *F. novicida* U112 and *F. novicida* CG57.

25

These results suggest that although *F. novicida* purA 1 is capable of infecting J774 mouse macrophages it is unable to replicate and that the infection can be cleared. It is possible that inside the macrophages the levels of adenine are

30



insufficient to enable the bacteria to multiply. The disruption of the *purA* gene may also have a detrimental effect on other cellular functions which would usually allow the bacterium to replicate and protect itself whilst inside the macrophage. It has been reported that *Francisella* enters macrophages by a cytochalasin B independent pathway, i.e. the bacteria are able to actively invade the macrophages rather than being taken up via microfilament mediated phagocytosis. However the difference in the number of bacteria recovered at T0 between *F. novicida* U112 and *F. novicida purA 1* implies that either the mutant is able to invade more successfully than the wildtype or that the macrophages are able to actively take up the *F. novicida purA* bacteria. This would suggest that the wildtype strain has a way of controlling its rate of invasion or uptake and that disrupting the *purA* gene has removed this control.

Although *F. novicida* CG57 grew at the same rate and to similar bacterial titres as *F. novicida* U12, twice the number of bacteria were initially used to infect the monolayer. Taking this into account *F. novicida* CG57 does appear to be slightly defective in its ability to replicate in J774 mouse macrophages. This supports the published data regarding this strain {Gray, et al. 2002 supra.}.

After 24 hrs the number of bacteria recorded at subsequent timepoints for *F. novicida* U112 and *F. novicida* CG57 begins to fall. This effect is caused by the way in which the bacteria are recovered from the assay. Replication of the bacteria in the macrophages causes them to detach from the base of the well, this was confirmed by examination of the monolayer under the light microscope. This means that washing of the monolayer removes these floating cells, therefore the number of bacteria counted only reflects those that were recovered from the monolayer. Thus the counts at the 24, 48 and 72 hr timepoints are likely to be an underestimation of the true numbers of bacteria per well. Microscopic examination of the monolayers

infected with *F. novicida* purA 1 showed that even after 72 hours the monolayers were intact and looked relatively healthy.

### Example 2

#### 5 Virulence challenge in mice

Bacterial cells from two spread plates were resuspended in 3ml PBS. This suspension was serially diluted to  $10^{-11}$ .

10 Spectrophotometer readings were taken at an optical density of 600nm of dilutions 0 to  $10^{-4}$ . Aliquots of 100 $\mu$ l of dilutions  $10^{-6}$ - $10^{-11}$  were plated in duplicate onto BCGA + supps and incubated for 24hr at 37°C. This was repeated for *F. novicida* U112, *F. novicida* CG57 and *F. novicida* purA1. Suitable dilutions were chosen depending on the required dose. Volumes of 100 $\mu$ l were given interperitoneally to Balb/c mice as described below.

15

To determine the median lethal dose (MLD) for *F. novicida* U112, groups of 5 Balb/c mice were immunised intra-peritoneally (IP) with a range of doses of between 0.01 and 115.5 cfu. (Table 5) From these results the MLD was calculated as 1.7 cfu. This level  
20 of virulence is comparable to the MLD of 1 cfu observed for the *F. tularensis* type A and type B strains. Therefore although *F. novicida* U112 has low pathogenicity in humans as compared to *F. tularensis* strains, this difference in virulence is not seen in the Balb/c mouse model.

25

Surviving mice were challenged with 100MLDs of *F. novicida* U112. No protection was observed.

Table 5

Strain immunised	Dose immunised	Number of survivors	Number of survivors after challenge with <i>F. novicida</i> U112
<i>F. novicida</i> U112	0.01cfu	5/5	0/5
<i>F. novicida</i> U112	0.11cfu	5/5	0/5

Strain immunised	Dose immunised	Number of survivors	Number of survivors after challenge with <i>F. novicida</i> U112
<i>F. novicida</i> U112	1.15cfu	3/5	0/3
<i>F. novicida</i> U112	11.5cfu	0/5	-
<i>F. novicida</i> U112	115cfu	0/5	-

***F. novicida* purA 1.**

To determine the MLD for *F. novicida* purA 1, groups of 5 Balb/C mice were dosed IP with a range of doses between 0.01-155cfu.

- 5 No deaths were observed. The mice were challenged with 100MLDs *F. novicida* U112 but no protection was seen in the immunised mice (Data not shown).

- 10 The dose was increased to between  $3.3 \times 10^2$  -  $3.3 \times 10^6$  cfu. No fatalities were observed so it was concluded that the MLD exceeded  $3.3 \times 10^6$  cfu.

- 15 The mice were challenged with 100MLDs of *F. novicida* U112 and it was shown that *F. novicida* purA 1 conferred some protection but this response was not dose dependent (Table 6).

**Table 6**

Strain immunised	Dose immunised	Challenge strain	Number of survivors
<i>F. novicida</i> purA 1	$3.3 \times 10^2$	<i>F. novicida</i> U112	2/5
<i>F. novicida</i> purA 1	$3.3 \times 10^3$	<i>F. novicida</i> U112	1/5
<i>F. novicida</i> purA 1	$3.3 \times 10^4$	<i>F. novicida</i> U112	0/5
<i>F. novicida</i> purA 1	$3.3 \times 10^5$	<i>F. novicida</i> U112	1/5

Strain immunised	Dose immunised	Challenge strain	Number of survivors
<i>F. novicida</i> purA 1	$3.3 \times 10^6$	<i>F. novicida</i> U112	1/5
Controls	-	<i>F. novicida</i> U112	0/5

#### *F. novicida* CG57

To determine the MLD for *F. novicida* CG57, groups of 5 Balb/C mice were dosed IP with a range of doses between 0.002 - 24.5.

5 No deaths were observed.

The mice were challenged with 100MLDs of *F. novicida* U112 (Table 7). From the results was observed that a dose of 24.5cfu of *F. novicida* CG57 could confer complete protection against a *F. novicida* challenge of 100MLDs.

10

**Table 7**

Strain immunised	Dose immunised	Challenge strain	Number of survivors
<i>F. novicida</i> CG57	0.002 cfu	<i>F. novicida</i> U112	0/5
<i>F. novicida</i> CG57	0.02 cfu	<i>F. novicida</i> U112	0/5
<i>F. novicida</i> CG57	0.24 cfu	<i>F. novicida</i> U112	2/5
<i>F. novicida</i> CG57	2.45 cfu	<i>F. novicida</i> U112	3/5
<i>F. novicida</i> CG57	24.5 cfu	<i>F. novicida</i> U112	5/5

15 The doses of *F. novicida* CG57 were increased to between  $1.58 \times 10^3$  -  $1.58 \times 10^7$  cfu. Deaths were recorded in the two groups that received the highest dose of *F. novicida* CG57 and from these results the MLD was calculated as  $6.67 \times 10^3$  cfu (Table 7). The survivors were challenged with 1000MLDs of *F. tularensis* LVS (which is lethal to mice). Survival of all the mice challenged

demonstrated that *F. novicida* CG57 at a dose of  $1.58 \times 10^3$  cfu or greater could protect against a *F. tularensis* LVS challenge (Table 8).

5    **Table 8**

Strain immunised	Dose immunised	Number of survivors	Survivors after challenge with <i>F. tularensis</i> LVS
<i>F. novicida</i> CG57	$1.58 \times 10^3$ cfu	5/5	5/5
<i>F. novicida</i> CG57	$1.58 \times 10^4$ cfu	5/5	5/5
<i>F. novicida</i> CG57	$1.58 \times 10^5$ cfu	5/5	5/5
<i>F. novicida</i> CG57	$1.58 \times 10^6$ cfu	1/5	1/1
<i>F. novicida</i> CG57	$1.58 \times 10^7$ cfu	0/5	-
Control	-		1/5

These results show that although the *F. novicida* purA' clone was highly attenuated in the Balb/c mouse model, it was not protective against a challenge of 100MLDs of *F. novicida* U112.

10

Although *F. novicida* GC57, which has an inactive *purF* gene was also defective for growth in mouse macrophages and was attenuated in the Balb/c mouse model, it was protective against a challenge of 100MLDs of *F. novicida* U112 and 100MLDs of *F. tularensis* LVS. This therefore indicates that such a strain could form the basis of a live attenuated vaccine.

15



## Claims

- 
1. A strain of *Francisella* species wherein a gene which encodes an enzyme in the purine pathway has been inactivated, and which  
5 is able to produce a protective immune response in an animal, for use as a live prophylactic or therapeutic vaccine against infection by said *Francisella* species.
2. A strain according to claim 1 wherein the gene is *purF*.  
10
3. A strain according to claim 1 or claim 2 wherein said gene is inactivated by complete or partial deletion mutation or by insertional mutation.
- 15 4. A strain according to any one of the preceding claims which is a strain of *Francisella tularensis*.
5. A strain according to claim 4 which is a strain of *Francisella tularensis* subspecies *tularensis*.  
20
6. A strain according to claim 4 which is a strain of *Francisella tularensis* subspecies *novicida*.
7. A pharmaceutical composition comprising a live strain of  
25 *Francisella* species wherein a gene, which encodes an enzyme in the purine pathway, has been inactivated, and which is able to produce a protective immune response in an animal, in combination with a pharmaceutically acceptable carrier.
- 30 8. A composition according to claim 7 wherein the gene is *purF*.
9. A composition according to claim 7 or claim 8 wherein said gene is inactivated by complete or partial deletion mutation or  
35 by insertional mutation.

10. A pharmaceutical composition according to any one of claims 7 to 9 wherein the strain is a strain of *Francisella tularensis*.

5 11. A pharmaceutical composition according to claim 9 wherein the strain is a strain of *Francisella tularensis* subspecies *tularensis* or a strain of *Francisella tularensis* subspecies *novicida*.

10 12. The use of a strain of *Francisella* species wherein a gene which encodes an enzyme in the purine pathway has been inactivated, and which is able to produce a protective immune response in an animal, in the preparation of a live prophylactic or therapeutic vaccine against infection by said *Francisella* species.

15

13. The use according to claim 12 wherein the gene is *purF*.

14. The use according to claim 12 or claim 13 wherein said gene is inactivated by complete or partial deletion mutation or by  
20 insertional mutation.

15. The use according to any one of the preceding claims wherein the strain is a strain of *Francisella tularensis*.

25 16. The use according to claim 15 wherein the strain is a strain of *Francisella tularensis* subspecies *tularenis* or a strain of *Francisella tularensis* subspecies *novicida*.

30 17. A method of preventing or treating infection by a *Francisella* species, which method comprises administering to an animal an effective amount of a live strain according to any one of claims 1 to 6 or a composition according to any one of claims 7 to 11.

35 18. A method according to claim 17 for preventing or treating infection by *Francisella tularensis*, wherein the strain of

*Francisella* species used in the method is a strain of *Francisella tularensis* subspecies *tularensis* or *Francisella tularensis* subspecies *novicida*.

---

- 5 19. A method for preparing a strain according to any one of claims 1 to 6, which comprises transforming a strain of *Francisella* species so as to inactivate said gene using cryotransformation.
- 10 20. A strain of *Francisella tularensis* subspecies *tularensis* wherein a gene that encodes a *purA* gene has been inactivated.

## Abstract

## Live vaccine Strain

- 5 A strain of *Francisella* species wherein a gene which encodes an enzyme in the purine pathway has been inactivated, and which is able to produce a protective immune response in an animal, for use as a live prophylactic or therapeutic vaccine against infection by said *Francisella* species. Suitable genes for  
10 inactivation include the purF gene.

Pharmaceutical compositions and methods which utilise these strains are also described and claimed.

1/7

Figure 1. The *de novo* purine pathway.






Figure 2. The pUC18 *guaA'* construct.




Figure 3.1




Figure 3.2





Figure 3.3



4/7

Figure 4.1.




Figure 4.2.





Figure 5. Growth after 48 hrs of *F. novicida*, *F. novicida* CG57 and *F. novicida* purA 1 in various supplemented media.





**Figure 6. *F. novicida* U112 and *F. novicida* GC57 growth over 24 hrs in CDM.**








Figure 7. Growth of *F. novicida* U112, *F. novicida* CG57 and *F. novicida* purA 1 in J774 mouse macrophages with 95% confidence intervals.



951/GB-004001264



This Page is inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox**